The Industry

September 2006
Pharmaceutical Representative;Sep2006, Vol. 36 Issue 9, p10
The article offers news briefs related to the pharmaceutical industry worldwide. Pfizer Inc. is going to sell its consumer healthcare business to New Jersey-based Johnson & Johnson for $16.6 billion. Switzerland-based Roche AG is going to have alliances with Actelion Ltd. and Evotec AG. Eli Lilly & Co. will sign a market and distribution agreement with Germany-based Daiichi Sankyo.


Related Articles

  • The Top 10: The Year In Review.  // Pharmaceutical Executive;May2010, Vol. 30 Issue 5, p78 

    The article provides updates in the U.S. pharmaceutical industry. Pfizer Inc. has acquired Wyeth for 68 billion dollars deal. Roche Holding AG has completed 47 billion dollars acquisition of Genentech Inc. Johnson & Johnson has acquired Elan's rights and assets in the Alzheimer's Immunotherapy...

  • EPE's First Annual Report of the World's Top 50 Pharma Companies.  // European Pharmaceutical Executive;Jul/Aug2005, p21 

    The article presents the first annual report published by the periodical "European Pharmaceutical Executive" of the top 50 pharmaceutical companies in the world. Companies belonged to top five are Pfizer Inc., GlaxoSmithKline PLC, Johnson & Johnson company, Merck Group company, Astrazeneca PLC,...

  • COMPANY SPOTLIGHT -- F. Hoffmann-La Roche.  // PharmaWatch: Monthly Review;May2010, Vol. 9 Issue 5, p25 

    The article presents a company profile for Basel, Switzerland-based F. Hoffmann-La Roche Ltd., one of the leading healthcare groups. It offers a strengths, weaknesses, opportunities, and threats (SWOT) analysis of the company's business situations, direction and position. It highlights the...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Jul2005, Vol. 4 Issue 7, p3 

    The article reports global developments related to the pharmaceutical industry. Large pharmaceutical groups including Novartis AG and Pfizer Inc. have entered into partnerships alongside companies with more humble resources. Roche Pharmaceuticals and GlaxoSmithKline PLC have gained top billing...

  • CORPORATE.  // MondayMorning;4/18/2011, Vol. 18 Issue 15, p2 

    The article offers news briefs related to the U.S. pharmaceutical industry. Roche Holding AG said that its first-quarter 2011 sales fell 9% with the decline in its revenue from the Avastin tumor drug and a stronger Swiss franc. Merck & Co. will resolve an arbitration dispute with Johnson &...

  • URCH Publishing Report: GlaxoSmithKline will overtake Pfizer to become world's largest pharmaceutical company by 2012.  // Chemical Business;Nov2008, Vol. 22 Issue 11, p82 

    The article focuses on a report, entitled "Pharmaceutical Market Trends, 2008-2012--Key market forecasts and growth opportunities," from URCH Publishing, which forecasts that Pfizer will fall from first to third place in the top ten company list. According to the report, the list in 2012 will be...

  • Big Pharma's Manufacturing Strategy: What Is the Next Move?  // Pharmaceutical Technology;Aug2010, Vol. 34 Issue 8, p32 

    The article focuses on the activities of several big pharmaceutical companies in the U.S. Accordingly, these pharmaceutical firms have modified their strategy to improve their respective business operation, research and development, and their manufacturing processes. It highlights the companies...

  • Three Things.  // Pharmaceutical Representative;Oct2009, Vol. 39 Issue 10, p9 

    The article offers developments in the pharmaceutical industry in the U.S. It states that cases of global cancer increased by 30 percent and by 2020, the number will increase by 17 million. Roche AG chief executive officer (CEO) Pascal Soriot will be the head chief operating officer (COO) of the...

  • Pharma, Generics Firms See More Green on the Other Side. Morrison, Trista // BioWorld Insight;2/22/2010, Vol. 18 Issue 8, p1 

    The article reports on the shift of U.S. pharmaceutical companies to generics. It keys out the benefits that generics offer to pharmaceutical companies such as its provision of deeper access to pharma firms in emerging markets and the granting of another route to drug makers for the continuance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics